Mumbai, India
Ajanta Pharma Ltd is a pharmaceutical company headquartered in Mumbai, India, with a strong presence in the Branded Generic business in India and Emerging markets, as well as the Generic business in the USA.
In India, the company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology, and Pain management, with brands that hold leadership positions in their respective sub-therapeutic areas.
Within Emerging Markets, the company has a presence in Africa, South East Asia, West Asia, and CIS, focusing on broader therapeutic segments such as antimalarial, gastro, antibiotics, cardiology, dermatology, and pain management.
As of 30th Sep 2024, Ajanta has 46 ANDA approvals which are commercialized. It holds 2 tentative approvals and 22 ANDAs are awaiting US FDA approval, with plans to file 8-12 ANDAs during the current financial year.
The company has state-of-the-art research facilities for formulation and API development in Mumbai, India, supported by a dedicated team of over 800 scientists working on R&D, and 6 formulations manufacturing facilities located in India.
Ajanta continuously invests in enhancing the existing manufacturing facilities to meet current cGMP requirements and in the construction of new facilities to support the company’s growth requirements.
For more information, please visit Ajanta Pharma Ltd.
